Older patients with small cell lung cancer and significant weight loss were more likely to experience dose interruptions than ...

NICE has said that Roche’s Tecentriq (atezolizumab) plus chemotherapy should be funded by the NHS as an option for untreated extensive-stage small-cell lung cancer (ES-SCLC) in second draft ...

Two impressive studies in lung cancer and another in breast cancer made Sunday a stellar day for AstraZeneca at the ASCO congress. Three of the group’s top cancer drugs were on display – EGFR ...